Market Cap (In TWD)
12.38 Billion
Revenue (In TWD)
767.66 Million
Net Income (In TWD)
274.65 Million
Avg. Volume
1.77 Million
- Currency
- TWD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 74.8-115.0
- PE
- 7.08
- EPS
- 12.17
- Beta Value
- 0.628
- ISIN
- TW0004162003
- CUSIP
- -
- CIK
- -
- Shares
- 143654000.0
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Hong-Ren Wang Ph.D.
- Employee Count
- -
- Website
- https://www.pharmaengine.com
- Ipo Date
- 2012-06-20
- Details
- PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan and Europe. It is developing ONIVYDE, a proprietary liposome encapsulation of irinotecan, a topoisomerase 1 inhibitor for the treatment of metastatic pancreatic cancer; PEP06, which is in Phase I clinical trial for the treatment of cancer; and PEP07, a Chk1 inhibitor, which is in preclinical development stage to accumulate DNA damage in cells, lead to replication catastrophe, and induce cell apoptosis. PharmaEngine, Inc. was incorporated in 2002 and is headquartered in Taipei, Taiwan.
More Stocks
-
FUTS
-
1626
-
600052
-
3658
-
OBT
-
600851
-
5302
-
SYSXSysorex, Inc.
SYSX